Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1988]

TargomiRs show promise in phase I study of malignant mesothelioma

Prof Nico van Zandwijk - University of Sydney, Sydney, Australia

TargomiRs show promise in phase I study of malignant mesothelioma ( Prof Nico van Zandwijk - University of Sydney, Sydney, Australia )

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL...

Dr Paula Cramer - University of Cologne, Köln, Germany

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL ( Dr Paula Cramer - University of Cologne, Köln, Germany )

Chemoresistance and residual disease promoted by DNMT3A R882 in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

Chemoresistance and residual disease promoted by DNMT3A R882 in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL

Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands

$Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )$

EHA 2015 highlights

Peter Goodwin - ecancer reporter

EHA 2015 highlights ( Peter Goodwin - ecancer reporter )

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Dr Jessica Okosun - Barts Cancer Institute, London, UK

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma ( Dr Jessica Okosun - Barts Cancer Institute, London, UK )

Biomarkers for childhood relapsed acute lymphoblastic leukaemia

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Biomarkers for childhood relapsed acute lymphoblastic leukaemia ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Are CML patients being treated to the correct standard?

Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany

Are CML patients being treated to the correct standard? ( Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany )

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM

Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM ( Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia )

Overview of innovation in Hodgkin's lymphoma

Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award

Overview of innovation in Hodgkin's lymphoma ( Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award )

Applications of chimaeric antigen receptor T-cells in leukaemia

Dr Carl June - University of Pennsylvania, Philadelphia, USA

Applications of chimaeric antigen receptor T-cells in leukaemia ( Dr Carl June - University of Pennsylvania, Philadelphia, USA )

Minimal residual disease in multiple myeloma

Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain

Minimal residual disease in multiple myeloma ( Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain )

More from ecancer